bioAffinity Technologies Files 8-K
Ticker: BIAFW · Form: 8-K · Filed: Oct 20, 2025 · CIK: 1712762
Sentiment: neutral
Topics: 8-k, filing, financials
Related Tickers: BIAF
TL;DR
BIAF filed an 8-K on 10/20/25 for other events and financials.
AI Summary
On October 20, 2025, bioAffinity Technologies, Inc. filed a Form 8-K to report other events and financial statements. The company, incorporated in Delaware with its principal executive offices in San Antonio, Texas, is involved in commercial physical and biological research.
Why It Matters
This filing indicates bioAffinity Technologies, Inc. is providing updates on its corporate activities and financial status to the SEC.
Risk Assessment
Risk Level: low — This is a routine filing of a current report (8-K) with no immediate indication of significant financial or operational changes.
Key Numbers
- 001-41463 — SEC File Number (Identifies the company's filing with the SEC.)
- 46-5211056 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- October 20, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Antonio, Texas (location) — Principal executive offices
- 8731 (sic_code) — Standard Industrial Classification
FAQ
What is the primary purpose of this Form 8-K filing?
The Form 8-K is filed to report other events and financial statements as of October 20, 2025.
When was the earliest event reported in this filing?
The earliest event reported is dated October 20, 2025.
In which state was bioAffinity Technologies, Inc. incorporated?
bioAffinity Technologies, Inc. was incorporated in Delaware.
What is the company's principal executive office address?
The principal executive offices are located at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.
What is the Standard Industrial Classification (SIC) code for bioAffinity Technologies, Inc.?
The SIC code is 8731, which falls under SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH.
Filing Stats: 568 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-10-20 16:15:52
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex99-1.htm (EX-99.1) — 14KB
- ex99-2.htm (EX-99.2) — 1KB
- ex99-1_001.jpg (GRAPHIC) — 25KB
- ex99-2_001.jpg (GRAPHIC) — 821KB
- 0001493152-25-018643.txt ( ) — 1437KB
- biaf-20251020.xsd (EX-101.SCH) — 4KB
- biaf-20251020_def.xml (EX-101.DEF) — 26KB
- biaf-20251020_lab.xml (EX-101.LAB) — 36KB
- biaf-20251020_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 20, 2025 BIOAFFINITY TECHNOLOGIES, INC. By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer -3-